13F-HR filed by GREAT POINT PARTNERS LLC
GREAT POINT PARTNERS LLC filed this 13F-HR for the quarter ended 2025-06-30, filed 2025-08-14, with 26 holding rows worth $153,801,796.
- Accession
- 0001172661-25-003478
- Filer
- CIK 1281446
- Filed
- 2025-08-14
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q2 2025
A holdings report, 26 entries on the cover page, a total value of $153,801,796 stated on the cover page (in dollars after the unit check, H1), rows summing to $153,801,796 with VALUE read as dollars as filed, 13F file number 028-11743. The quarter's positions are built on this report. The resolved quarter.
Other managers
- included managerJAY JEFFREY R028-12517
- included managerNordahl Lillian028-24470
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| IONIS PHARMACEUTICALS INC COM | 462222100 | Stock | 500,000 | $19,755,000 | dollars as filed | |
| REZOLUTE INC | 76200L309 | COMMON STOCK | 3,033,462 | $13,529,241 | dollars as filed | |
| AMYLYX PHARMACEUTICALS INC | 03237H101 | COM | 2,000,000 | $12,820,000 | dollars as filed | |
| LEGEND BIOTECH CORP | 52490G102 | SPONSORED ADS | 350,000 | $12,421,500 | dollars as filed | |
| ABIVAX SA- | 00370M103 | SPONSORED ADS | 1,291,617 | $9,880,870 | dollars as filed | |
| NEUROGENE INC | 64135M105 | COMMON STOCK | 485,859 | $7,263,592 | dollars as filed | |
| AKEBIA THERAPEUTICS INC | 00972D105 | COMMON STOCK | 1,985,915 | $7,228,731 | dollars as filed | |
| EVOLUS INC | 30052C107 | COM | 720,118 | $6,632,287 | dollars as filed | |
| ARCELLX INC COMMON STOCK | 03940C100 | Stock | 100,000 | $6,585,000 | dollars as filed | |
| XENON PHARMACEUTICALS INC COM | 98420N105 | Stock | 200,000 | $6,260,000 | dollars as filed | |
| AKERO THERAPEUTICS INC | 00973Y108 | COM | 103,848 | $5,541,329 | dollars as filed | |
| JADE BIOSCIENCES INC | 008064206 | COM NEW | 498,054 | $4,975,559 | dollars as filed | |
| CYTOKINETICS INC | 23282W605 | COM NEW | 150,000 | $4,956,000 | dollars as filed | |
| IMMUNOVANT INC | 45258J102 | COM | 262,176 | $4,194,816 | dollars as filed | |
| UNICYCIVE THERAPEUTICS INC | 90466Y202 | COMMON STOCK | 796,558 | $3,799,582 | dollars as filed | |
| KALVISTA PHARMACEUTICALS INC | 483497103 | COM | 323,170 | $3,653,437 | dollars as filed | |
| TAYSHA GENE THERAPIES INC | 877619106 | COMMON STOCK | 1,500,000 | $3,465,000 | dollars as filed | |
| DBV TECHNOLOGIES S A | 23306J309 | SPONSORED ADS | 374,679 | $3,432,022 | dollars as filed | |
| ZURA BIO LTD | G9TY5A101 | COMMON STOCK | 3,170,194 | $3,328,704 | dollars as filed | |
| UPSTREAM BIO INC | 91678A107 | COMMON STOCK | 300,000 | $3,294,000 | dollars as filed | |
| CONTEXT THERAPEUTICS INC | 21077P108 | COM | 4,683,711 | $3,068,767 | dollars as filed | |
| CENTESSA PHARMACEUTICALS PLC | 152309100 | SPONSORED ADS | 225,000 | $2,956,500 | dollars as filed | |
| SCHOLAR ROCK HLDG CORP | 80706P103 | COM | 61,607 | $2,182,120 | dollars as filed | |
| PROMIS NEUROSCIENCES INC | 74346M406 | COM NEW | 2,645,128 | $1,279,713 | dollars as filed | |
| PLIANT THERAPEUTICS INC | 729139105 | COM | 850,000 | $986,000 | dollars as filed | |
| HELIX ACQUISITION CORP II | G4444H101 | CL A ORD SHS | 29,381 | $312,026 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001172661-25-003478 | this filing | 2025-08-14 | acceptance time not in the bulk data set |